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Abstract 
Microarray analysis of human hepatic aging 
David W. Boorman 
Andres Kriete, PhD 
 
 
 
 
Two sets of liver tissue samples of human subjects were investigated by gene expression microarray 
analysis. One set had normal and disease samples with their telomere lengths; the other set consisted of 
groups of normal young and old donors, mostly post mortem. The goal was to identify genes related to 
aging and inflammation and to investigate the hypothesis that telomere length is a biomarker for these 
processes. 
 
The first set of ten surgical liver biopsies were run on the single channel microarray, Codelink Human 
Bioarray.  Because of the liver diseases in the subjects (3 with Hepatitis C, 3 with Primary Sclerosing 
Cholangitis, 1 with a liver cyst, and 3 controls), the standard preliminary procedure of simple variance 
filtering was deemed insufficient. Instead, the samples were adjusted for disease using Analysis of 
Covariance, to identify genes of potential interest. This was conducted in three pairs based on age, telomere 
length and disease, because of the small sample size. With this procedure, about 1,600 genes had an alpha 
significance of less than five percent (14.7% total for all comparisons). Hierarchical clustering of these 
genes grouped the Hepatitis C patients and the young patients, as a partial validation of this model. 
 
The second dataset was obtained from the Gene Expression Omnibus (GEO), GSE9588. The samples were 
run on the Rosetta/Merck Human 44k 1.1 dual channel microarray platform, against a control of 191 
pooled human liver samples. The original study analyzed the surgical and post mortem liver samples with 
respect to disease and single nucleotide polymorphisms.  Sixty-seven samples were selected from this 
dataset, ages 20-29 or ages 70-81.  Their telomere lengths are unknown.  Simple variance filtering resulted 
in 1,965 differentially expressed genes. 
 
To reduce false positives further, various microarray techniques were employed, including hierarchical 
clustering, principal component analysis, k-means clustering and Pavlitis Template Modeling. The last 
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technique matches expression to the relative telomere length or age. Resulting genes were then run through 
the gene ontology programs DAVID and PANTHER, which find gene networks.  
 
Networks that were differentially up regulated based on age include ubiquitin, a protein intracellular 
transport marker often linked to protein targeted for degradation, as well as cytochrome p450 (CYP), a 
mono-oxygenase in the endoplasmic reticulum of hepatocytes involved in the breakdown of steroids, fatty 
acids and xenobiotics. The cytochrome p450 network was up regulated in the older group, but not in elderly 
who also had steatosis (fatty liver) or who had drug liver risk from the use of a medication. Networks down 
regulated or mixed based on age included the broad categories of "receptors" and "immunity and defense."  
IL8, which is involved in inflammation, was one of these hits. Networks that were down regulated with 
shorter telomere length included genes related to chromatin restructuring and transcription regulation, 
including the selective down regulation of several Histone H4 isoforms. 
 
Hypotheses generated from this study include the identification of six poorly characterized receptors which 
may be involved in liver regeneration. Additionally, there may be a mechanistic problem between CYP 
transcription and activated protein, because of the high CYP mRNA levels seen here in elderly, compared 
to the unchanged or decreased protein levels found in other studies. Additionally, elderly with steatosis or 
drug liver risk may have a higher hepatocyte turn over and higher Hepatocyte Growth Factor (HGF) 
expression, since HGF suppresses CYP. 
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INTRODUCTION 
 
Overall Goals 
 
The purpose of this study is to identify genes and gene networks in the human liver which are differentially 
regulated by biological age. This will help with understanding the aging process, and understanding 
differences in physiology which might be relevant in the treatment of diseases. 
 
Review of Aging Theories 
 
Theories of why people age can generally be categorized into three major groups:  The Good of the Species, 
Evolutionary Aging Theory and Rate of Living [1, 2]. 
 
The Good of the Species theory basically states that if aging did not occur, the necessary turnover of 
generations would not occur, and the species would not improve, evolve and adapt. The theory's problems 
include that it confuses death with aging; we could be young and beautiful, and then die. Additionally, the 
urge of an individual to reproduce would win out evolutionarily to an ideal zero population growth. 
 
The geneticist Haldane theorized that Huntington's Disease, which is caused by a dominant mutation in the 
huntingtin protein, is less affected by natural selection because Huntington's Disease does not manifest 
itself until midlife. Medawar expanded this theory to aging, creating the Evolutionary Aging Theory. This 
theory states that any gene that affects the body only late in life is virtually immune to natural selection.  
 
The majority of gene mutations are harmful, and some genes have multiple effects. For example, 
testosterone has evolutionary beneficial effects, such as encouraging muscle development, but suppresses 
the immune system, accelerates the deterioration of arterial walls and increases the risk of prostate cancer. 
Evolution would tend to encourage higher expression of testosterone, despite these harmful effects; this is 
known as antagonistic pleiotrophy. 
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More generally, animals that are more efficient at repelling predators tend to live longer because they do 
not need to reproduce as quickly to survive. This explains the general trend of longer life among larger 
animals, but also explains exceptions to this rule, such as birds, bats, the quahog clam, which has the 
longest life recorded at about two hundred years, and others. Flying squirrels live about 17 years, versus 7-
8 years for chipmunks and 2-3 years for rats. Island animals which have fewer predators also tend to live 
longer than their mainland counterparts. 
 
The proponents of the Rate of Living Theory include Max Rubner and Raymond Pearl. Studies show that 
in general, larger animals have slower metabolic rates and tend to live longer [3]. Others [2] showed that 
longevity in rats can be increased by decreasing diet consumption. While there is a general trend with this, 
there are important exceptions to this rule in a number of small animals with long lives which are not 
explained by this theory. Birds and bats both have very long lives relative to their relative metabolism. In 
bats, this was suspected to be caused by their hibernation. However, tropical bats that do not hibernate are 
just as long lived. Additionally, the total number of heart beats of a water flea are about the same whether 
in cold water, which slows their heart rate, or warm water. Marsupials have metabolic rates 70-80% of that 
of other animals the same size, but marsupials are shorter lived. Sacher's animal experiments predict an 
expenditure of 200-300 kcal/g per lifetime, but humans live about four times as long as predicted, with an 
expenditure of 800 kCal/g. 
 
The rate of living theory is strongly associated with the generation of reactive oxygen species (ROS) 
through oxidative metabolism in mitochondria [4]. With the development of molecular biology, this theory 
has received particular attention in the search for molecular mechanisms behind aging process. 
Mitochondria are highly dynamic organelles, attracted to cytosolic sites of high ATP demand and undergo 
constant fission and fusion. However, there is substantial complexity in the process from free radical 
generation to mitochondrial DNA damage and loss of mitochondrial turnover, normally modulated by 
antioxidant and repair pathways [5], and further regulated by the mechanisms of uncoupling proteins 
(UCPs), which belong to a class of mitochondrial inner-membrane proteins [6]. Since ROS is highly 
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diffusible, damage to mitochondrial proteins and DNA closest to the origin of ROS production are most 
likely, but oxidation of proteins can occur throughout the cell. Interestingly, it has been suggested that ROS 
preferentially oxidizes resident proteins in the ER [7], making ROS the primary cause not only for 
mitochondrial, but also for ER dysfunction. 
 
Telomere Shortening 
 
With the discovery of cellular senescence in-vitro [8], another mechanism contributing to the aging process 
was discovered, the shortening of telomeres. Telomeres are repeated DNA sequence, GGGTTA in humans, 
that are about 10,000 base pair long, and found at the ends of chromosomes. Each time the cell divides, the 
telomere gets 50-100 bases shorter, because the DNA polymerase falls off the end before it completes 
replication. In the absence of telomerase, which is capable of relengthening the telomeres, the cell will 
enter senescence when the telomeres become short enough, and the cell will no longer divide. This 
corresponds with changes in gene expression [9]  This serves in part as a control mechanism for 
carcinogenesis. 
 
Aging and Disease 
 
Disruption of mitochondrial function, generation of ROS and cellular oxidative damage has been associated 
with chronic inflammation implicated in a host of degenerative disease states including osteoarthritis, 
atherosclerosis, type-2 diabetes and even cancer [10-12]. Age-associated chronic inflammatory states are 
distinct from inflammation triggered by infection. It is presently unclear to what extent chronic 
inflammatory states in older individuals represent autoimmune processes caused by deregulation of the 
immune system [13, 14]. Alternatively, these states may arise as a consequence of an increased oxidative 
stress response in old cells triggered by molecular damage incurred over a lifetime. In support of cell-
autonomous causes for age-associated inflammation, expression of inflammatory markers such as cytokines, 
has been observed in cells subjected to replicative senescence in vitro caused by serial passaging [15-18].  
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Liver and Aging 
Although the liver is more regenerative than other organs, age does not spare the liver, in particular because 
its one of the most metabolically active organs. Both hepatic blood flow and total liver volume decrease 
with age [19, 20], as does its metabolic activity. As within other cell types, reactive oxidative species 
damage DNA. Mitochondrial DNA is especially prone, because it has fewer means to correct errors from 
mutations [21]. Response to disease is also changed; for example, people infected with Hepatitis C virus 
after 40 years of age will progress more quickly to fibrosis [22]. 
Steroid and Drug Metabolism in the Liver 
A major function of the liver is to metabolize both steroids and xenobiotic molecules. Typically, this is 
categorized into two phases. Phase I involves the oxidation of the molecule, while Phase II involves 
conjugation to make the molecule water soluble, so it can be excreted by the kidney. Cytochrome p450 
(CYP) is an example of a Phase I protein family, while glutathione s-transferase (GST) is an example of a 
Phase II protein family. Many drugs are poorly eliminated in the elderly. However, this is not necessarily 
because of reduced CYP activity. Other physiological changes such as reduced renal capacity, reduced 
hepatic blood flow and reduced liver volume most likely play a large role [23]. 
Cytochrome p450 
 
One protein family which became particularly important for this study is cytochrome p450, located in the 
endoplasmic reticulum. Cytochrome p450 (CYP) are a family of heme-thiolate monoxygenases (adds a 
single oxygen to a molecule). It is part of an NADPH-dependent electron transport pathway. It oxidizes a 
variety of structurally unrelated compounds:  steroids, fatty acids and xenobiotics. The first three or four 
families oxidize most xenobiotics, along with other endogenous substrates. Table 1 below lists some 
families and drugs they metabolize [23, 24].  
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Table 1:  Principal Characteristics of Cytochrome p450 Enzyme Families 
 
 
 
Regulation of Cytochrome p450 (CYP) Gene Expression and Transcription 
This study involves the use of microarrays, which simultaneously measures the mRNA levels (gene 
expression) of all 30,000 genes in a sample at once, including 2000 genes related to metabolism, and 70 
cytochrome p450 genes (including ten clones or ESTs). This allows us to identify gene networks which are 
differentially expressed. Regulation of CYP transcription can generally be affected by a variety of factors 
other than age:  genetic background, nutritional status, presence of disease, and previous exposure to other 
xenobiotics. It is regulated by hormones, such as growth hormones and thyroid hormones. It is induced by 
alcohol, eating cruciferous vegetables or charcoal-broiled beef. Some families are down regulated by 
grapefruit juice, calcium blocking drugs or other drugs. Diseases such as hepatocellular carcinoma and 
insulin-dependent diabetes mellitus (which cause hormonal perturbations) can also change regulation of 
cytochrome p450 [23]. 
 
 
 
Family Sub-
family 
Endogenous 
Biosynthesis 
Typical Drug 
Substrate 
Role in Bioacti-
vation (Drugs) or 
Function 
(Endogenous) 
Inducibility 
by Chemicals 
Isoforms Up 
Regulated in 
This Study. 
CYP1 A 
B 
 Theophylline 
Theophylline 
Very extensive 
Very extensive 
Very high 
High 
CYP1A1 
-- 
CYP2 A 
B 
C 
D 
E 
 Propranolol 
Coumadin 
Tolbutamide 
Debrisquine 
Chlorzoxazone 
Limited 
Limited 
Poor 
Poor 
Extensive 
Modest 
High 
Modest 
Not inducible 
High 
2A6, 2A7, 2A13 
CYP2B6 
CYP2C8 
CYP3 A  Erythromycin Limited High CYP3A4, 3A7 
CYP5-8  Thromboxane 
prostacyclin  
 Biosynthesis   
CYP7 A Cholesterol  Degradation  CYP7A1 
CYP26  Retinoic Acid  Transcription reg.  CYP26A1 
CYP51  Cholesterol, 
Bile acids 
 Biosynthesis  CYP51A1 
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MATERIALS AND METHODS 
Materials and Methods Introduction 
 
Datasets 
 
Two datasets were used in this analysis. The first dataset consisted of ten liver samples obtained and 
processed by us. The second dataset was obtained from the National Institutes of Health's Gene Expression 
Omnibus (GEO) database, identification number GSE9588. Both datasets are described in more detail 
below. 
 
Liver Diseases in These Datasets 
 
Primary Sclerosing Cholangitis (PSC) 
PSC is a chronic, slow progressing disease which causes scarring and inflammation of the liver ducts. 
Scarring leads to bile accumulation, which leads to cirrhosis. Blockage leads to occasional bile infections. 
Liver transplants are often needed at late stages. The cause is unknown, although about 70% of those 
affected are men. There is no cure or specific treatment [25].  
 
Hepatitis C 
Hepatitis C is a virus transmitted through contact with blood, usually by sharing injecting needles. About 
15-40% of those infected are able to clear the infection in the early stages. The remaining develop chronic 
infections, which can be symptomless for long periods. It can lead to cirrhosis, liver failure and liver cancer. 
The virus can be treated with a 50% success rate by the antiviral drugs, peginterferon and interferon [25]. 
However, antiviral treatment is generally not recommended for the elderly, due to a lower rate of response 
and a higher rate of adverse effects [26]. 
 
Liver Cysts 
Liver cysts are benign encapsulated growths [25]. 
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Steatosis  (GEO GSE9588 Dataset) 
Steatosis, or fatty liver, is the buildup of fat within hepatocytes, defined when the fat comprises more than 
ten percent of the total liver weight. Often there are no symptoms, but it can lead to inflammation of the 
liver. It can be caused by obesity, diabetes and high triglyceride levels, as well as by alcohol abuse, rapid 
weight loss and malnutrition. Treatment includes diet change, exercise, control of diabetes, limitation of 
triglyceride intake, and abstaining from alcohol consumption. [25]  A population survey in Italy found 
steatosis through ultrasound in 16.4% of the general population, 46.4% of heavy drinkers, 75.8% of obese 
subjects, and 94.5% of heavy drinkers who are obese [27]. 
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MATERIALS AND METHODS 
Ten Liver Samples - Description and Data Processing 
 
Tissue Preparation and Microarray Platform 
 
From this study, RNA was isolated from liver tissue obtained from ten live patients who were already 
undergoing the surgical liver biopsy for medical reasons [28]. Qiagen RNeasy mini kit was used according 
to the manufacturer's instructions. Gene expression analysis was performed using the Codelink Human 
Bioarray containing more than fifty thousand single-stranded 30-mer oligonucleotide probes and single dye 
labeling (Applied Microarrays, Tempe, AZ). Chips were run in duplicate. Details of this platform are 
available on the vendor's homepage website. Characteristics of the Codelink platform have been previously 
evaluated by us [29] and as part of the microarray quality control (MAQC) assessment [30]. Sample 
preparation and hybridization followed procedures previously described [29]. The data were normalized 
according to the manufacturer's instructions. Average telomere restriction fragment (TRF) length of the 
hepatocytes was determined by restriction enzyme digestion, gel electrophoresis, and radioactive label 
hybridization, described elsewhere [28]. 
 
Population Demographics 
 
The ten liver tissue samples came from patients aged 21-61, and with telomere lengths 6.2 - 9.0. Since the 
liver biopsies were performed on live patients undergoing the biopsy for medical reasons, most also had a 
liver disease, which complicates the analysis. There were three patients with Hepatitis C virus, three with 
Primary Sclerosing Cholangitis (scarring of the liver ducts), one with a liver cyst, and three with no known 
liver diseases. To give an overview of the population demographics, we plotted telomere length versus age 
with their diseases, as shown in Figure 1 below. Ellipses show the consistent grouping of the samples by 
hierarchical clustering using a number of different distance metrics, discussed further in the Results section. 
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Telomere vs. Age
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Figure 1:  Population demographics of the ten liver samples by average telomere length, patient's 
age, and by the patient's disease. Hierarchical clustering of the samples consistently grouped the 
three patients with Hepatitis C and the three patients aged 21-29. 
 
 
 
ANCOVA Rationale 
Typically with microarray analysis, the standard method in one of the first steps is a broad variance filter of 
the genes. The vast majority of the genes represented by the 54,000 probes are either not expressed, or are 
not differentially expressed (aka "housekeeping genes"). This initial filter screens out most of the genes 
where expression is mostly absent or "flat" across the samples, greatly reducing the size of the dataset, so it 
can be examined more closely with more sensitive methods. It achieves this by a straightforward check of 
the variance across the difference samples. Those probes with too little variance are removed. 
 
Because of the small relative sample size and the complexity of the population, this method was deemed 
inadequate. The presence of three variables (age, disease and telomere length) makes discriminating 
between them difficult. Equally important, it is likely that a real difference based on age would be masked 
by noise created from the other variables. 
 
This problem was addressed by adjusting for the diseases using Analysis of Covariance (ANCOVA), 
instead of simple variance filtering as a preliminary screen of the genes. ANCOVA has been applied 
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previously to microarray analysis by other researchers, but in the context of a Bayesian framework. [31]  
ANCOVA is a type of General Linear Model (GLM) which combines multiple linear regression with 
Analysis of Variance (ANOVA), in an additive fashion. Figure 2 below has the expression profile a gene in 
the dataset which would probably have been discarded with a simple variance filter, to illustrate the overall 
increase in power using ANCOVA. By adjusting for the disease in Figure 3, the strong differential change 
of expression based on telomere length becomes apparent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2:  Linear regression of the RNA expression of the probe for ZNF 431 show s a low 
adjusted R2 of 0.19, and an insignificant slope (p=.11). This gene most likely would have been 
discarded by a simple variance filter. Equation: y=2.68-0.21*Tel  R2adj=0.19 F=3.14 p=0.11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3:  The data of the same gene are adjusted data for disease using ANCOVA. With this 
added information, the adjusted R2 rises to 0.79 with a significant slope (p=.01). This shows that 
in fact the gene is most likely differentially regulated based on telomere length, and would be 
included in the subset.  Eq'n: y=5.56-0.52*Tel-0.51*PSC-0.95*HepC  R2adj=0.79  F=10.7; p=0.01 
ANCOVA of ZNF 431
Telomere Length with Disease
y = 5.56 - 0.52*Tel - 0.51*PSC - 0.95*HepC
R2adj = 0.79  F=10.7  p=.01
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Sample Data Processing 
 
Removal of Bad Data Points 
All samples were normalized using the protocol presented by microarray chip manufacturers. Data points 
which had background contamination, were irregularly shaped, or otherwise unreliable were removed. This 
represented 3.475% of the data points.  
 
Censored Data 
Because ANCOVA relies on a linear model, "left censored" data had to be addressed. The general shape of 
the fluorescent intensity curve for microarrays is sigmoid. That is, as the sensitivity of the microarray 
approaches the background noise level, the fluorescent signal does not linearly reflect the mRNA 
expression level of the sample. Additionally, it is assumed that the majority of human genes will not be 
expressed at any time, but will still show some signal due to variations in the background noise level. These 
variations become accentuated when the data is transformed with a log 2 transform as described below.  
 
For this reason, the Negative TrimMean Control, which is the normalized median fluorescent intensity of 
the negative controls, was used as the baseline for "background noise."  All fluorescent intensity readings 
below this level were artificially raised to it.  
 
Ideally, "right censored" data where the signal becomes saturated should also be addressed. However, 
because the positive controls (in the form of standardized bacterial RNA spikes) did not provide as clear of 
a cut point as the Negative TrimMean Control, and because only about 250 genes had signals above the 
positive control signals that were provided, we deemed it unnecessary to adjust the upper end of the signal. 
 
Log 2 Transform and Duplicate Averaging 
The microarray chips were run in duplicates. The data were log 2 transformed, and then averaged 
afterwards, to reduce the impact of potential outliers. If one of the data points were bad or missing, the 
other data point was taken as the average instead. If both data points were bad or missing, the data point 
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was considered missing as well. Replicas which were greater than eight fold different in intensities (that is, 
that had a log 2 difference greater than 3) were removed as being unreliable. 
 
Repeated measures analysis (in place of averaging the data points first) was deemed to be unnecessary, 
since we were not interested in internal variations. Additionally, ANCOVA relies on equal variance, which 
is not a reasonable assumption for microarrays, given the number of potential places in the procedure where 
an aberrant intensity reading might be introduced. One aberrant intensity reading could grossly inflate the 
variance, resulting in the entire gene being discarded.  
 
Data Normality 
Since ANCOVA depends on normally distributed data, this was checked individually for each gene (each 
row), using Excel's skewness and kurtosis functions. The data was deemed insufficiently normal and the 
gene was discarded if one of these values was greater than ± 2*SES or SEK, respectively. The Standard 
Error of Skewness (SES) was estimated as n/6 , while the Standard Error of Kurtosis (SEK) was 
estimated as n/24  [32].  
 
Removal of Genes with Unknown Function 
After the data preprocessing, genes with unknown functions were removed. This included clones, 
expressed sequence tags (EST), proprietary probes of companies, and others. 
 
ANCOVA Filtering 
 
XL-Stat and ANCOVA Macro 
To facilitate a simple ANCOVA analysis of each gene, the program XL-Stat was used (www.XLStat.com). 
This program by the company Addinsoft (Paris, France) is a supplemental program which runs with 
Microsoft's Excel software, allowing Excel to handle more advanced statistical analysis, and eliminating 
the problems associated with transferring data and learning a new syntax for another program. A macro was 
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written which automatically ran the ANCOVA analysis for each gene. See Appendix B.10 for the code. 
Data had to be run in sets of no more than three thousand, because of computer RAM memory issues.  
 
Application of ANCOVA for This Dataset 
Only genes which had nine or ten data points (up to one missing) were used. Because there were a 
maximum of ten samples per gene in this dataset, the ANCOVA could not be performed simultaneously 
against age, telomere length and disease, as would be the normal procedure. Instead, the ANCOVA was run 
three separate times in pairs:  age-disease, age-telomere length and telomere length-disease. The Type I 
error for falsely rejecting the null hypothesis was set at α=0.05 for each pair, giving a total Type I error of 
0.147 for at least one false rejection of the null hypothesis, calculated as follows:  P(X≥1) = 1 - P(X=0) = 1 
- (0.95)3 = 0.147. Since this is only the preliminary filtering step, additional analysis (hierarchical clustering, 
etc.) and gene ontology network identification reduces the real Type I error further to a more acceptable 
level. Because a regression line cannot be created from a single point, the patient with liver cyst disease had 
to be removed with the age-disease and telomere-length disease adjustments. 
 
Appendix C lists the Excel code used to preprocess much of the data, including the ANCOVA macro code. 
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MATERIALS AND METHODS 
GEO Liver Dataset GSE9588 - Description and Data Processing 
 
Original Study 
 
In May 2008, Schadt et al published a microarray analysis of 427 human liver tissue samples from 
postmortem and live surgical sources [33].  Their study involved linking microarray expression analysis to 
single nucleotide polymorphisms (SNiPs), to identify and validate susceptibility genes, and to understand 
how changes in the networks lead to changes in disease traits, including obesity, diabetes and 
atherosclerosis.  The data were adjusted in the analysis for age, sex and center at which the tissue was 
processed. The normalized datasets were posted on the National Institutes of Health's Gene Expression 
Omnibus (GEO) as GSE9588, prior to making adjustments. It was log base ten transformed, and censored 
to -2 and +2.  
 
Dual Channel Microarray Platform 
The microarray platform used is the Rosetta/Merck Human 44k 1.1 platform (GPL4372), which consists of 
39,302 60-mer gene probes, of which 1,228 are not publically classified. This dual channel array uses RNA 
from a control and experimental sample, each labeled with a different dye, that competitive binds to the 
same microarray probe. The control used was a pooled sample of liver RNA from 191 subjects, labeled 
with the Cy3 dye channel. The individual subjects were labeled with the Cy5 dye. The samples were 
processed and analyzed in the protocol previously described [33]. 
 
Data Preprocessing 
For this analysis, the data was transformed from log 10 to log 2. A simple variance filter captured the 1,965 
probes which had a variance of at least 5% of mean standard deviation of the top one hundred genes. This 
subset was used in all subsequent analyses. 
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GSE9588 Population Demographics 
 
The dataset was taken from GEO and matched against the population demographics of the subjects. 
Subjects were selected who were within the age range of 20-29 or 70-81. Subjects whose ages were 
imputed were removed. Additionally, several subjects (n=11) were removed because of a significant 
number of missing intensity data points across the genes. The result was 67 Caucasian subjects within these 
age ranges. Almost a quarter had drug liver risk (medications which affect liver function), because of use of 
prescription and over the counter medication. One third of the young and one sixth of the old had steatosis 
(fatty liver), although steatosis was more severe in some of the older subjects. There was one subject in 
each group with known alcohol risk, although patient data for this category was mostly missing. See Table 
2 below. 
 
 
Table 2:  Population Demographics of Subjects Used from GEO Dataset GSE9588. 
Age Range # Gender # Drug Liver Risk DLR Steatosis Alcohol Risk 
20-29 years 25 Female 6 
Male 19 
No 19 = 5 F; 14 M 
Yes 6  = 1 F;  5 M 
Mild 7; 2 w/DLR  
Moderate 1;  
Severe 0; 
No 8 known 
Yes 1 known 
(w/out DLR) 
70-81 years 42 Female 24 
Male 18 
No 34 = 19 F; 15 M 
Yes 8  = 5 F; 3 M 
Mild 4; 1 w/DLR 
Moderate 1; 
Severe 2; 2 w/DLR 
No 8 known 
Yes 1 known 
 (w/DLR) 
 
 
 
Medication Use 
Medication use was not recorded in all cases; none of those in the young group had medications record. In 
the older group, most were related to heart or possibly stroke conditions, as follows:  Coumadin 
(anticoagulant); Diovan (angiotensin II receptor antagonist for high blood pressure and congestive heart 
failure); HCTZ (diuretic) and ketoprofen (non-steroid anti-inflammatory, pain killer, reduces fever); Plavix 
(anticoagulant) and insulin (diabetes); Ecotrin (coated aspirin) and Ziac (diuretic); Coumadin 
(anticoagulant) and Lasix (diuretic). 
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MATERIAL AND METHODS 
Microarray Analysis 
 
Data preprocessing resulted in a subset of 1,561 genes for the ten liver samples, and 1,965 genes for the 
GEO liver. 
 
TiGR MeV, DAVID and PANTHER 
After data preprocessing, all subsequent microarray analysis for both liver sets were conducted with the 
TM4 TiGR MultiExperiment Viewer (MeV) 4.0 and the MultiArray Viewer open-source program, 
available at www.tm4.org/mev.html [34]. Log transformation and variance filtering of the GEO dataset, 
previously mentioned, were also conducted with TiGR MeV. Gene code conversion and gene ontology 
clustering were conducted with the National Institutes of Health's DAVID, the Database for Annotation, 
Visualization, and Integrated Discovery, available at http://david.abcc.ncifcrf.gov [35]. Additional gene 
ontology clustering and pathway identification was conducted with PANTHER, Protein ANalysis THrough 
Evolutionary Relationships, available at www.PantherDB.org [36] [37]. 
 
Analysis A - Ten Liver Samples 
 
Distance Metric 
For Hierarchical Clustering (HCL), Self Organizing Tree Algorithm (SOTA), K-means Clustering, Self 
Organizing Map (SOM), Cluster Affinity Search Technique (CAST), QT Cluster and others, the distance 
metric used was Pearson's Correlation. 
 
Pavlidis Template Matching 
In addition to the standard clustering methods, the Pavlidis Template Matching was used. Patient age was 
converted to a ratio between 0 and 1, using the following formula:  (patient age - min. age) / (max. age - 
min. age). The minimum age was 21, the max age was 61. This identified genes whose expression matched 
this ratio. By subtracting the ratio from 1, genes down regulated with age were identified. A similar 
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formula was used to identify genes up and down regulated by average telomere length. Minimum telomere 
length: 6.2. Maximum telomere length: 9.0. Figure 4 shows how this template matching occurs. 
 
 
 
Figure 4:  Pavlidis Template Matching by average telomere length, with samples loaded by telomere length. 
Blue line (bottom):  telomere length ratio (0 to 1). Pink line (top): cluster of 83 genes with the closest 
matching expression pattern. Sample labels on x-axis omitted for space considerations. 
 
 
 
Analysis B - GEO Liver Dataset GSE9588 
 
Distance Metric 
For Hierarchical Clustering (HCL), Self Organizing Tree Algorithm (SOTA), K-means Clustering, Self 
Organizing Map (SOM) and others, the distance metric was selected which was best able to cluster the 
samples by their age group, or which created a gene expression cluster differentiated by the age group. This 
metric was almost always the Average Dot Product, although the Pearson Correlation metric also came 
close, and the Pearson.Uncentered metric was used once.  
 
T-test, SAM and ANOVA 
In addition to these methods, two group comparisons were made with a t-test and with Significance 
Analysis for Microarrays (SAM). A two-factor ANOVA was also employed twice, with age against gender 
or against drug liver risk. 
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RESULTS 
Ten Liver Samples 
 
Hierarchical clustering by several different distance metrics 
continuously clustered the three patients with Hepatitis C and the 
three youngest patients, ages 21-29, which partially validates the 
ANCOVA filtering method as a model. See Fig. 5.  
 
Figures A1 - A12 in Appendix A show some of the expression 
patterns found by various clustering methods. 
 
Differential expression was divided into four categories:  up regulated by chronological age, down 
regulated by age, up regulated with shorter telomere length, down regulated with shorter telomere length. 
Note:  shorter average telomere lengths correspond to an older cellular age. 
 
Out of the subset of 1,561 genes, the following number of genes was found to be differentially regulated: 
 
Age Up: 227 genes 
Age Down: 136 genes 
Tel. Up: 81 genes 
Tel. Down: 159 genes 
 
These genes were loaded into DAVID and PANTHER, using all genes on the microarray as background, to 
identify pathways, biological processes and molecular functions which had a higher than expected 
representation. DAVID bases its analysis on an "Enrichment Score," with a higher number being better. 
Only enrichment scores greater than 1.0 were reported. PANTHER calculates a p-value based on a Chi-
square test comparing the observed number of genes to the number expected to appear by random chance. 
Figure 5:  Hierarchical clustering 
groups the 3 Hepatitis C patients 
(…HepC) and the 3 youngest 
patients (21PSC, 24Cont, 29PSC). 
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P-values less than 0.05 were selected. Tables 3and 4 below show details of the results. In DAVID, genes 
which appear indented in the same table cell are "children" (subsets) of the larger category. 
 
Differentially Regulated Biological Processes and Molecular Functions: 
Age Up: Ubiquitin-protein ligase; Golgi apparatus; zinc finger proteins 
Age Down: Immunity and defense; receptor; metal cation channels 
Telomere Up: None detected. 
Telomere Down: Histones; chromatin packaging and remodeling (strong hits: p=E-15 & E-12) and 
transcriptional regulation. 
 
Table 3:  DAVID Functional Analysis Clusters of Ten Liver Samples 
Expression Cluster Enrichment Score # genes 
Age Up Ubiquitin 1.46 14
Age Up Golgi 1.23 6
Age Up Zinc Finger 1 39
Age Down Metal Cation Channel 1.01 23
Telomere Up (None >1.0)   
Telomere Down Transcription Regulation 1.47 34
 
 
Table 4:  PANTHER Analysis of Ten Liver Samples. 
Analysis Expression Description Ref List Obs. Expect p-value 
Molecular 
Function Age Up 
Ligase 
 * Ubiquitin-protein ligase 
374 
187 
13 
10 
4.71 
2.36 
3.01E-02
2.48E-02
Biological 
Process Age Down Immunity and defense 1137 20 8.42 8.61E-03
Molecular 
Function Age Down Receptor 1220 22 9.04 2.69E-03
Biological 
Process 
Telomere 
Down 
Nucleoside, nucleotide and 
nucleic acid metabolism 
 * Chromatin packaging  
    and remodeling 
2732 
 
191 
31 
 
16 
14.95 
 
1.04 
1.09E-03
1.64E-12
Molecular 
Function 
Telomere 
Down 
Nucleic acid binding 
 * Histone 
2132 
72 
30 
14 
11.66 
0.39 
1.87E-05
1.08-15
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RESULTS 
GEO Liver Dataset GSE9588 
 
These analyses identified 165 differentially regulated genes, of which approximately 130 were up regulated 
in the older group. Genes up regulated by age group consistently clustered by several different methods in 
an unexpected way. Expression in the young group was generally low. The older group spontaneously 
clustered into two subgroups with these genes: with and without drug liver risk or steatosis. The genes in 
the elderly without drug liver risk were up regulated. However, the genes in the elderly with drug liver risk 
or with severe steatosis (fatty livers) were down regulated, the same as the younger group. These clusters 
were the only ones which were identifiably clustering based on age group. Figure 6 below shows this 
unexpected clustering behavior. 
 
 
 
Figure 6:  Up regulated. K-means clustering of the sample group. Left side: young (n=25). Right 
side: older, beginning with the first up regulated subject. The second down regulated group are 
young old F no DLR F St & DLR M no DLR DLR 
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older females with mild steatosis (n=2) and drug liver risk (n=5), of which the last two had severe 
steatosis. Two older males without drug liver risk were also down regulated.  The last three 
subjects are older males with drug liver risk. This pattern was consistent across several different 
clustering methods. 
 
 
 
Clustering also produced about 37 genes with an approximately reversed expression profile, although this 
pattern was much less consistent and strong. See Figure 7 below. 
 
 
Figure 7:  Down regulated. SOTA cluster by the Pearson Uncentered metric resulted in 37 genes 
which were generally down regulated among older subjects without drug liver risk (right side). 
The second group near zero are older females with drug liver risk (n=5) with severe steatosis 
(n=2), and females with mild steatosis (n=2 of 3). The last three subjects are males with drug liver 
risk. This pattern was less clear cut and less consistent than the opposite regulatory pattern. 
 
 
 
Age Up: Nicotine degradation pathway;  
Steroid and fatty acid metabolism; carbohydrate metabolism;  
Electron transport; oxygenase and reductase; dehydrogenase; cytochrome p450 
young old F no DLR F St & DLR M no DLR DLR 
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Glutathione s-transferase. 
Mixed: Immunity and defense; chemokines; Interleukin 8. 
Age Down: Antibacterial response protein 
 
 
Table 5: Significantly Regulated Pathways, Biological Processes and Molecular Functions in the 
GEO Postmortem Liver Set GSE9588, Identified by PANTHER 
Type Expression Description Ref List Obs.  Expect p-value 
Pathway Age Up  Nicotine degradation 9 3  3 0.05 3.44E-03
Biological 
Process Age Up 
Lipid, fatty acid and steroid metabolism 
 * Fatty acid metabolism 
 * Steroid metabolism 
  - Steroid hormone metabol. 
699 
163 
170 
42 
17 
6 
15 
5 
15 
 6 
14 
 5 
3.96 
0.92 
0.96 
0.24 
1.37E-05
5.15E-02
1.04E-11
9.49E-04
Biological 
Process Age Up  
Carbohydrate metabolism 
 * Other carbohydrate metabolism 
534 
53 
10 
4 
 9 
 4 
3.03 
0.3 
2.94E-02
3.69E-02
Biological 
Process Age Up  Electron transport 221 11 11 1.25 1.93E-06
Molecular 
Function Age Up  
Oxidoreductase 
 * Oxygenase 
 * Reductase 
550 
94 
157 
19 
12 
6 
19 
12 
 6 
3.12 
0.53 
0.89 
8.93E-09
5.97E-11
4.70E-02
Molecular 
Function Age Up  Dehydrogenase 205 6  6 0.84 3.23E-02
Molecular 
Function Age Up  
Transferase 
 * Other transferase 
799 
119 
13 
6 
12 
 
4.53 
0.67 
1.77E-02
1.06E-02
Biological 
Process Age Mixed Immunity and defense 1188 17 12 6.73 1.17E-02
Molecular 
Function Age Mixed 
Signaling molecule 
 * Chemokine 
726 
46 
14 
4 
 9 
 2 
4.11 
0.26 
1.87E-03
2.40E-02
Molecular 
Function Age Down 
Defense/immunity protein 
 * Antibacterial response protein 
320 
34 
8 
3 
 5 
 3 
1.81 
0.05 
1.45E-02
3.68E-03
 
 
 
Table 6:  Functional Clusters of the GEO Postmortem Liver Set GSE9588 Found by DAVID 
Express #  Cluster name Enrichment Score # Genes 
Class 
stringency Genes 
Age Up 1 Cytochrome p450 7.56 14 Low All similar cytochrome p450 
Age Up 2 Reductases 3.23 3 Low 
Steroid 5 alpha reductase 
Cytochrome p450 
Aldo-keto reductase 
Age Up 3 Glutathione s-transferase 2.83 4 Low All similar glutathione s-transferases 
Age Up 4  2.33 4 Low 
pregnancy-zone protein 
secreted phosphoprotein 2 
zymogen granual protein 16 
fetuin b 
Age Up 5  2.3 3 Low 
clusterin-like 1 
growth differentiation factor 15 
fetuin b 
Age All 6 Interleukin 8 2.99 5 Medium IL8 chemokine (c-c motif) ligand  
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DISCUSSION 
 
Use of ANCOVA 
 
While using ANCOVA is thought to have improved the overall power of the analysis, it does have 
limitations associated with assumptions of the test. While some assumptions like normal distribution could 
be tested directly and automatically, several others could not. In most cases, violations of these assumptions 
lead to a reduction of power and an omission of a gene that might be of importance. For example, this is 
true of the assumption of linearity and homogeneity of slopes. With linearity, a non-linear curve is difficult 
to assess with only three data points per category. Despite these limitations, the overall power and accuracy 
should be increased, and outweighs some of the genes that may be lost in the process. 
 
Left Censored Data 
 
Additionally, some protocols recommend discarding genes which show no expression. The drawback of 
this is that it can be difficult to distinguish between a gene with low expression and a gene with no 
expression. More importantly, a gene which goes from no expression to expression is as important as a 
gene which goes from low expression to high expression. Raising the expression values to the Negative 
TrimMean Control, which differs for each chip, eliminates this problem. Analysis of genes which were at 
this lower level for all samples confirmed that the ANCOVA removed them from the subset of genes used 
in further analysis. 
 
Genes Up Regulated with Chronological Age 
 
Several gene ontology clusters were up regulated with age. In the ten sample dataset, this includes 15 
ubiquitin related genes and six genes of the Golgi apparatus. In the GEO dataset, this includes 37 genes 
related to cytochrome p450, oxidoreductases and detoxification. 
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Ubiquitin Enzymes Up Regulated with Age in the 10 Sample Dataset. 
 
In the ten sample dataset, both DAVID and PANTHER found an up regulation of genes related to ubiquitin, 
which is a protein tag for intracellular translocation. A consecutive series of ubiquitin tags targets a protein 
for degradation [9]. An up regulation of these enzymes could indicate an increase in the number of proteins 
that are not folding properly. Another poorly characterized gene was down regulated (SDCCAG10, Entrez 
ID 10283), which is thought to accelerate protein folding, as was a negative regulator of NFκB and 
ubiquitin (PPIL5, Entrez ID 122769). Table B1 in Appendix B lists the specific ubiquitin genes that were 
up regulated, along with their functions. 
 
Cytochrome p450 Up Regulated with Age in GEO Dataset GSE9588 
 
In the GEO dataset, there were a number of biological processes and molecular functions that are all related 
to cytochrome p450 (CYP):  electron transport, oxygenase, reductase, fatty acid metabolism and steroid 
metabolism. These were highlighted by both DAVID and PANTHER. There was low expression among 
the young, and among the elderly who had steatosis or drug liver risk. However, expression was high 
among the elderly without steatosis or drug liver risk. These results were strong and internally very 
consistent, appearing repeatedly with several different microarray clustering algorithms, usually using the 
Average Dot Product distance matrix.  
 
CYP in Other Studies 
However, the results are unexpected, and appear to conflict with other studies, such as several that show a 
reduced clearance of CYP3A xenobiotic substrates in the elderly [38], or others which show an overall 
decrease in surface area of smooth endoplasmic reticulum in rats [39]. There are conflicting results, and 
variability between subjects tends to be large [40]. 
 
Two larger studies looked at CYP expression. Both of these studies investigated actual protein 
concentrations and enzymatic activity, rather than at mRNA expression levels. The first study of 54 human 
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subjects [41] found no difference between age groups with cytochrome p450 expression. The second study 
of 226 human subjects [42] found a significant decrease in CYP concentration among the elderly group.  
 
However, our results correlate very closely with a third study [43]. This particular microarray study is 
limited because of a very small sample size (two rat and two human livers), and because they compared a 
one-year old infant to a 78 year old, instead of using a young adult. They found at least a three-fold 
increase in both CYP and GST genes, including CYP1A1, CYP1A2 and CYP2C18 (not up regulated in this 
study), as well as GSTA2 and GSTT2. They confirmed mRNA up regulation of CYP1A1 and CYP2C18 
using RT-PCR. They tested GST activity using CDNB, and found a small, insignificant decrease in GST 
activity in the 78 year old. 
 
A fourth microarray study of rats [44] found mixed differential expression in thirteen CYP genes, split 
approximately equally between up and down regulation. This includes a decrease in four CYP3A isoforms 
(contrasted with an increase here). The study involved 15, 10 and 13 rats at 32, 58 and 84 weeks of age, 
respectively. None of the specific CYP isoforms differentially expressed were identical to the isoforms 
found up regulated in this study. They also found mixed differential regulation of Phase II metabolic 
enzymes, including glutamine s-transferase (GSTA2, GSTA5 and GSTT1).  
 
It is possible that results from this study are biased by an unidentified confounder, such as possibly 
differences in post mortem versus surgical hepatic biopsies, differences in the center processed, different 
diseases or cause of death, or differences in care and treatment. 
 
If the up regulation is related to steroid metabolism, it could indicate a feedback mechanism designed to 
reduce the impact of a chronic presence of steroids, perhaps due to chronic inflammation signals or similar 
chronic signal. The up regulation of genes in the Golgi complex may be a secondary effect of this change. 
Since those older patients taking medications were down regulated, this probably does not affect xenobiotic 
metabolism. It is possible that those people on medications were generally receiving better care, and were 
in a more "natural" state than those who were not on medications.  
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Alternatively, this could reflect a reduced regenerative capability in the elderly. A microarray study of 
transgenic mice which over express hepatocyte growth factor (HGF) had revealed an overall decrease of 
several CYP genes after partial hepatectomy [45]. The elderly with drug liver risk or steatosis who did not 
show an increase in CYP gene expression may have had conditions which stressed the body, which may 
have resulted in HGF release. Several appear to have had heart conditions while others were probably 
obese. This goes in hand with the decrease in receptors  possibly related to regeneration in the ten sample 
set, discussed below. 
 
Combining these results with those from the ten sample dataset, which showed an increase in ubiquitin, 
could suggest that there is a problem occurring between transcription and activated enzyme, with the body 
attempting to compensate by increasing transcription. Similarly, the body may be trying to compensate for 
the general decrease in hepatic blood flow and volume. 
 
Generally, these results indicate changes in biosynthesis. Recent work has demonstrated a connection 
between endoplasmic reticulum (ER) stress in the cytoplasm and diabetes, where protein unfolding in 
response to ER stress is hypothesized to disrupt processes associated with diabetes [33]. The unfolded 
protein response has also been linked to inflammation and oxidative stress [33], thus offering a relationship 
between the above discussed molecular changes in metabolism and inflammatory markers. 
 
Receptors Down Regulated by Age in 10 Sample Dataset 
 
Out of the 23 receptors down regulated with age, approximately half were related to the immune system, 
described below. The remaining eleven receptors were generally not well characterized. However, six of 
them appear to be related either to development (unspecified, cardiac or mesoderm), cell proliferation or "--
genesis" (angiogenesis, neurogenesis, or oncogenesis). It is possible that these receptors are involved in 
liver regeneration, suggesting either a decreased ability of aged liver to regenerate, or perhaps to 
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differentiate into hepatocytes and other liver cells.  Liver regeneration is thought to decrease with age [39]. 
Table B2 in Appendix B lists all receptor genes with their known functions. 
 
Immunity and Defense: Down Regulated by Age in Ten Sample Dataset and 
 Mixed Regulation by Age in GEO Dataset GSE9588 
 
Ten Sample Dataset 
In the ten sample dataset, PANTHER found these genes down regulated with age. Of the twenty genes, five 
are cytokines or chemokines, six are expressed in immune cells themselves, with the remaining having 
other functions. Table B3 lists the genes. Since this dataset had seven people with diseases, the decrease in 
expression with age reflects a decreased ability to attract immune cells, and a decreased ability of the 
immune system to respond to diseases presented: Hepatitis C and Primary Sclerosing Cholangitis. 
 
GEO Dataset GSE9588 
In the GEO dataset, 17 genes were differentially regulated, but not in a consistent direction. Five of the 
genes up regulated are related to glutamine s-transferase, which group with cytochrome p450 genes. Of the 
seven others up related, three are involved in inflammation, which has been shown to increase with age in a 
recent microarray rat study [46]. For the five genes down regulated, three are chemotaxins, which matches 
results from the ten sample dataset. The other two are apolipoproteins. Table B4 lists the genes and their 
specific functions.  
 
Histones and Transcription Down Regulated with Shorter Telomeres - Ten Sample Dataset 
 
In the ten sample dataset, PANTHER found strong down regulation of several Histone H4 genes, and 
chromatin packaging and remodeling. In addition to the histones themselves, there were several ribosomal 
proteins. The remaining genes were principally related to transcription regulation. Table B6 lists the 
specific genes that were down regulated, along with their functions. As telomeres become shorter, cells go 
into replicative senescence to exit the cell cycle. When they do, chromatin condenses in particular in areas 
usually used for replication [47], in chromatin areas described as senescence-associated heterochromatic 
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foci (SAHF) [48]. While biological conclusions can be drawn with the results from the PANTHER tool, it 
is unknown why DAVID had no hit using the same dataset. Since ribosomes are part of the ER, down 
regulation may indicate less resident ER protein turnover/biogenesis, increasing the likelihood for 
dysfunction. It is unclear why only Histone H4 would be found to be down regulated, since this subunit 
normally works in conjunction with Histone H2A, H2B and H3 proteins in the nucleosome [9]. 
 
Genes Up Regulated with Shorter Telomere Length - Ten Sample Dataset 
 
Although microarray clustering found more than 120 genes up regulated with shorter telomere length, 
neither DAVID nor PANTHER were able to find genes within that group that had similar gene ontologies 
or networks. This could either indicate a large number of false positives, or a network system more 
complicated than either program could decipher. 
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CONCLUSION AND HYPOTHESES 
Conclusion 
 
We have shown that by using specific statistical techniques we can identify a molecular transcription 
profile in old and diseased liver specimen that are related to shortened telomeres, thus linking a 
phenotypically accessible marker in tissues with specific molecular events. It is very much debated whether 
telomere shortening contributes to the aging process, since rodents, for example, have much longer 
telomeres than humans that do not go beyond a critical length in old age [9]. Observations of molecular 
changes as they occur with telomere shortening as shown here, even accelerated with disease as reported 
previously [28], confirm the critical role of telomeres as these changes go along with a general architectural 
change in liver, including alterations in the cellular composition and inflammatory infiltration [28]. 
However, observational studies cannot decipher cause and effect and the sequence of events, but rather 
dedicated experiments will be needed. 
 
In summary, these microarray studies found an increase in ubiquitin and cytochrome p450 related genes 
with increasing chronological age. Some receptors had decreased with chronological age. Immunity and 
defense genes showed mixed differential expression with age. Shorter telomere length was associated with 
a decrease in expression of several Histone H4 genes, as well as other genes related to transcription 
regulation. A pattern in genes up regulated with shorter telomere length could not be found. 
 
Microarrays have proven extremely useful as a hypothesis generating tool. Here, we present seven 
hypotheses from the results found in this study. 
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CONCLUSION AND HYPOTHESES 
Hypotheses 
 
Hypothesis 1:   Six receptors (below) are linked to liver regeneration. 
Reasoning: Six receptors apparently involved in some aspect of development were down 
regulated with age in the ten sample set. All but ENG are poorly characterized, at 
least with regard to liver expression. Since liver regeneration decreases with age, 
these receptors may play a role in liver regeneration, with cell proliferation or 
differentiation. See also Table B2 in Appendix B. 
 
Entrez ID Gene Symbol Gene type Known or Suspected Function  
2022 ENG Endoglin Angiogenesis via TGF-β 
2041 EPHA1 Ephrin receptor Neurogenesis 
10154 PLXNC1 Plexin Tyr. kinase; IL6 & IL8 secretion 
169611 OLFML2A Olfactomedin-like Neurogenesis 
64123 ELTD1 EGF latrophilin 7 transmemb. G-protein coupled receptor;  
   cardiac development 
10234 LRRC17 Leucine Rich Repeat Development processes 
 
Hypothesis 2a: Elderly are less able to respond effectively to liver diseases than the young. 
Hypothesis 2b: Elderly are more prone to chronic inflammation of the liver than the young. 
Reasoning: Decrease in immunity and defense genes in elderly subjects with diseases. Increase 
in immunity and defense genes related to inflammation. 
 
Hypothesis 3: Elderly have more problems with protein misfolding in the liver than the young. 
Reasoning: Increase in ubiquitin systems in the elderly, along with a decrease in transcription 
with shorter telomeres. 
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Telomere Hypotheses: 
Hypothesis 4: Senescent hepatocytes have lower overall rates of transcription than non-senescent 
hepatocytes. 
Reasoning: Shorter telomeres correspond to senescent hepatocytes. Decreased expression of 
ribosomes and genes related to transcription in those with short telomeres. 
 
Hypothesis 5a: Chromatin in the nucleus of senescent hepatocytes is more condensed in senescent 
cells. 
Hypothesis 5b: A portion of the condensed chromatin does not require the presence of Histone H4. 
Reasoning: Decrease in several Histone H4 proteins in those with short telomeres. 
 
Cytochrome p450 Hypotheses: 
 
Hypothesis 6a: CYP mRNA levels do not correlate linearly with CYP activated protein levels in the 
elder; mRNA levels are higher than CYP protein concentrations would predict. 
Hypothesis 6b: CYP activated protein levels are low in the elderly because of decreased mRNA 
stability, problems with protein folding, decreased CYP stability or increased 
inactivation of CYP. 
Hypothesis 6c: A feedback mechanism induces CYP and GST transcription in the elderly, in an 
attempt to compensate for low CYP activated protein levels and/or low hepatic blood 
flow. 
Reasoning: High CYP mRNA levels in the elderly that were found in this study do not seem to 
correlate with other studies which have found no change or decreased activated CYP 
protein in the elderly. Hepatic blood flow is generally lower in the elderly. Also, 
ubiquitin enzymes were found to be up regulated in this study. 
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Hypothesis 7a:  Hepatocyte turnover is higher in elderly with steatosis or drug liver risk than elderly 
without steatosis or drug liver risk. 
Hypothesis 7b: Hepatocyte Growth Factor (HGF) levels are higher in elderly with steatosis or drug 
liver risk than they are in elderly without steatosis or drug liver risk. 
Reasoning: HGF suppresses CYP expression. CYP is higher in elderly without steatosis or drug 
liver risk than in elderly with steatosis or drug liver risk.  
 
These hypotheses could be tested with a variety of molecular biology techniques that are currently available, 
such as proteomics and immunohistochemistry. Some, such as the CYP hypotheses, would only require 
measuring mRNA, protein levels and protein activity from the same liver. Others, such as identifying the 
feedback mechanism, would require more a more elaborate experimental design. The enduring problem 
with this, of course, is the difficulty of obtaining a human liver biopsy, since it is not ethical to obtain these 
from healthy volunteers, due to the risk of infection. 
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Appendix A - Cluster Expression Profiles 
 
 
 
 
Ten Liver Samples - Age Up Ten Liver Samples - Age Down 
 
 
 Fig. A1: CAST Cluster, age up, 13 genes Fig. A2: CAST Cluster, age down, 43 genes 
 
 
 Fig A3: KMC, age up, 173 genes. Fig. A4 KMC age down, 98 genes 
 
 
Fig. A5: QTC, age up, 45 genes Fig A6:  QTC, age down, 47 genes 
 
 Fig A7: PTM, age up, 95 genes Fig A8: PTM, age down, 81 genes 
  Top line: actual cluster;  Top line: actual cluster; 
  Bottom: age ratio   Bottom:  reversed age ratio 
 
Ten Liver Smpl - Telomere Long-Short Up Ten Liver Smpl - Telomere Long-Short Down 
 
 Fig A9:  PTM Tel. Long-Short Up, 120 genes Fig A10: PTM Tel. Long-Short Down 83 genes 
 Top line: actual cluster; Bottom: rev. tel. ratio Top line: actual cluster; Bottom: telomere ratio 
   
 
 
 
Fig. A11:  QTC Telomere Long-Short Up #1, 37 genes 
 
 
 
 
Fig. A12:  QTC Telomere Long-Short Up  #2, 26 genes 
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Appendix B  Tables of Gene Regulation 
 
 
List of specific genes up or down regulated by age or telomere length for each dataset. Telomere expression 
direction refers to regulation from longest to shortest (i.e. by increasing cellular age). 
 
Table Category Subset Type Age/Tel. Expression Dataset 
B1 Ubiquitin ligase Function Age Up 10 smpl 
B2 Receptor Function Age Down 10 smpl 
B3 Immunity & Defense Function Age Down 10 smpl 
B4 Immunity & Defense Function Age Mixed GSE9588 
B5.1 Cytochrome p450 Biological Process Age Up GSE9588 
B5.2 Cytochrome p450 Molecular Function Age Up GSE9588 
B5.3 Cytochrome p450 Substrates & Function Age Up GSE9588 
B6 Transcription Reg. Function Telomere Down 10 smpl 
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Table B1: Genes Up Regulated by Age - Ubiquitin Ligases - 10 Sample Set 
 
E
nt
re
z 
G
en
e 
ID
 
G
en
e 
Sy
m
bo
l 
Gene Type 
U
bi
qu
iti
n 
pr
ot
ei
n 
lig
as
e 
or
 li
ga
se
 
(p
ar
en
t) 
L
iv
er
 E
xp
re
ss
io
n 
O
rg
an
 o
f m
aj
or
 
ex
pr
es
si
on
 
C
el
lu
la
r 
L
oc
at
io
n 
Function 
6477 SIAH1 Seven in ab-sentia homol. 
Ubi-
Ligase Lo 
Down reg. 
in HCC 
Cyt; 
nucl (lo) 
Ubiquitin & degradation of 
proteins 
8924 HERC2 Hect domain & RLD 2 
Ubi-
Ligase       E3 ubiquitin ligase? 
9690 UBE3C 
Ubiquitin 
protein ligase 
E3 
Ubi-
Ligase   
Skeletal 
muscles Nucl E3 ubiquitin ligase 
23077 MYCBP2 MYC binding protein 
Ubi-
Ligase       
Tuberin ubiquination and 
degradation through PAM? 
26054 SENP6 
SUMO1/sentri
n specific 
peptidase 
Ubi-
Ligase   
Testis, ov-
ary, prost. Nucl 
Activation of SUMO 
(ubiquitin-like molec.) 
57154 SMURF1 
SMAD 
specific E3 
ubi. pro. ligase 
Ubi-
Ligase       
For SMADs specific to 
bone morphogenic protein 
(BMP) pathway 
51320 RKHD2 ring finger and KH domain 
Ubi-
Ligase       
RNA binding. 
Posttranscriptional 
regulation? 
83737 ITCH 
Itchy homolog 
E3 ubi. protein 
ligase 
Ubi-
Ligase Y   
Cyt; 
nucl 
Regulates several 
transcription factors; 
immune response? 
92979 MARCH9 
Membrane-
asso-ciated 
ring finger 
Ubi-
Ligase       
Sorting of MHC-I, CD4 and 
ICAM1 to lysosomes? 
7726 TRIM26 Tripartite motif 
Ubi-
Ligase     Cyt 
Unknown; DNA binding? 
MHC I? 
2180 ACSL1 Acyl-CoA sythetase Ligase Hi   
Mit, 
ER, 
Peroxis. 
Activation of fatty acids for 
lipid synthesis or fatty acid 
degradation 
23305 ACSL6 Acyl-CoA sythetase Ligase   
Brain; 
hemato-
poetic cells 
Mit, 
ER, 
peroxis. 
Activation of fatty acids for 
lipid synthesis or fatty acid 
degradation 
3376 IARS 
Isoleucine-
tRNA 
synthetase 
Ligase       Links isoleucine tRNA to its amino acid 
10283 SDCCAG10 Colon Cancer antigen 
Im-
mun 
& Def. 
Down regulated. Not well 
characterized. Accelerates protein folding. 
122769 PPIL5 Peptidylprolyl isomerase Liver  Down regulated. 
Neg. regulator of NFkB; 
ubiquitin 
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Table B2: Genes Down Regulated by Age - Receptors - Ten Sample Dataset [35, 36] 
 
Entrez 
Gene 
ID 
Gene 
Symbol Gene Type 
Organ or Cell 
known to 
express 
Cellular 
Location Function or Ligand 
Im
m
un
ity
 a
nd
 
D
ef
en
se
 
D
ev
el
op
m
en
t o
r 
--
ge
ne
sis
? 
1370 CPN2 Carboxypeptidase   Secreted   Y  
1436 CSF1R Colony stimulating factor receptor   Membrane 
CST controls 
macrophages Y  
3598 IL13RA2 IL 13 receptor   Membrane Internalizes IL13? Not a signal mediator Y  
3820 KLRB1 Killer cell lectin-like receptor 
Natural killer 
cell Membrane 
Regulation of NK 
cell function? Y  
3822 KLRC2 Killer cell lectin-like receptor 
Natural killer 
cell Membrane 
MHC Class I 
molecule Y  
3823 KLRC3 Killer cell lectin-like receptor 
Natural killer 
cell Membrane 
MHC Class I 
molecule Y  
26253 CLEC4E C-type lectin domain 
Peritoneal 
macrophages Membrane 
Immune surveillance 
processes?  
Inflammation role? 
Y  
50856 CLEC4A C-type lectin domain Dendritic cells Membrane 
Inflammatory and 
immune response. Y  
83953 FCAMR Fc receptor for IgA, IgM     Unknown Y  
51338 MS4A4A Membrane span-ning 4-domains 
Hematopoietic 
cell lines Membrane 
Signal transduction? 
Pseudogene? Y  
64231 MS4A6A Membrane span-ning 4-domains 
B-cell, mono-
cyte cell lines Membrane Unknown Y  
2022 ENG Endoglin Vascular endo-thelial cells Membrane 
TGF-beta. Binding of 
endothelial cells. 
Angiogenesis, 
oncogenesis. 
N Y 
2041 EPHA1 EPH receptor 
Over 
expressed in 
carcinomas 
Membrane 
Ephrin. Neuro-
genesis, mesoderm 
devel., cell prolif. 
N Y 
10154 PLXNC1 Plexin C1   Membrane 
Viral receptor; endo-
genous unknown, 
devel. processes. 
N Y 
169611 OLFML2A Olfactomedin-like   Membrane Unknown; neurogenesis N Y 
64123 ELTD1 EGF, latrophilin transmembrane Smooth cells Membrane 
Cardiac 
development? N Y 
10234 LRRC17 Leucine rich repeat Liver-low   
Unknown; extra-
cellular matrix. De-
velopment processes. 
N Y 
203190 LGI3 Leucine rich repeat High in brain and lung Secreted 
Unknown; 
extracellular matrix N N 
219527 LRRC55 Leucine rich repeat     Unknown; extracellular matrix N N 
2893 GRIA4 Glutamate receptor Nerve cells Membrane Glutamate neurotransmission N N 
9936 CD302 CD 302 molecule      Endocytosis N N 
55697 VAC14 Vac 14 homolog      Unknown N N 
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Table B3: Genes Down Regulated by Age in Ten Sample Set - Immunity & Defense Genes [35] [36] 
 
Entrez  
Gene 
ID 
Gene 
Symbol Gene Type 
Organ or cell 
expression 
Cellular  
Location Function 
1370 CPN2 Carboxypeptidase   Secrete Unknown 
1436 CSF1R 
Colony 
stimulating factor 
receptor 
  Membrane 
Receptor for CST1, cytokine 
controls production, differentiation 
and function of macrophages 
2162 F13A1 Coagulation Factor XIII Liver; plasma 
Cytoplasm;  
Secreted Coagulation cascade 
3134 HLA-F MHC Class I   ER, Golgi Major Histocompatibility Complex
3433 IFIT2 Interferon-induced protein   Unknown Unknown 
3598 IL13RA2 Interleukin 13 receptor   Membrane 
Internalizes IL13?  Not a signal 
mediator 
3603 IL16 Interleukin 16   Secreted Cytokine. Chemoattractant of CD4+ lymphocytes 
3820 KLRB1 Killer cell receptor NK cells Membrane Regulation of NK cell function? 
3822 KLRC2 Killer cell receptor NK cells Membrane   
3823 KLRC3 Killer cell receptor NK cells Membrane   
5366 CCL21 Chemokine  (C-C motif) T-cell lines   Chemokine 
6368 CCL23 Chemokine  (C-C motif) Liver-high Secreted Cytokine. Chemoattractant 
7980 TFPI2 Tissue factor pathway inhibitor Liver-high Secreted Blood clotting. Plasmin inhibitor. 
9516 LITAF TNF factor Liver; spleen   NFkB transcriptional regulation of a chemokine 
10283 SDCCAG10 Colon Cancer antigen     Accelerates protein folding. 
26253 CLEC4E C-type lectin domain   Membrane 
Immune surveillance processes?  
Inflammation role? 
50856 CLEC4A C-type lectin domain Dendritic cells Membrane 
Inflammatory and immune 
response. 
55303 GIMAP4 GTPase IMAP family member T- & B-cells   GTPase activity 
115908 CTHRC1 Collagen triple helix repeat 
Chondrocyte-
like cells Secreted Neg. regulator of collagen matrix 
122769 PPIL5 Peptidylprolyl isomerase Liver   Neg. regulator of NFkB; ubiquitin 
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Table B4: Genes Up or Down Regulated by Age - GSE9588 Dataset - Immunity & Defense 
Subcategory 
 
Entrez 
ID 
Gene 
Symbol Gene Type  
C
Y
P 
re
la
te
d?
 
C
el
lu
la
r 
L
oc
at
io
n Function or ligand 
1401 CRP C-reactive protein  N Secreted Antibacterial; cytokine; DNA scavenger 
6288 SAA1 Serum amyloid  N Secreted (plasma) Apolipoprotein of HDL complex 
6289 SAA2 Serum amyloid  N   Dysfunctional form of SAA1; related to obesity and inflammation 
6374 CXCL5 Chemokine (C-X-C motif) ligand  N Secreted 
Chemotaxin for neutrophil activation; 
inflammation 
6364 CCL20 Chemokine (C-C motif) ligand  N Secreted Chemotaxin for lymphocytes 
9650 CCL4L1 Chemokine (C-C motif) ligand  N   Inflammation mediated by chemokine 
3576 IL8 Interleukin 8  N Secreted Inflammation mediated by chemokine 
2205 FCER1A Fc fragment of IgE, high affinity  N Membrane IgE receptor involved in allergy response. 
2353 FOS v-fos osteosarcoma oncogene  N Nucleus Transcription factor with JUN/AP-1 
3164 NR4A1 Nuclear receptor  N Nucleus 
Orphan nuclear receptor induced by 
growth hormones; translocation to 
mitochondria induces apoptosis 
5858 PZP Pregnancy-zone protein  N   
Blood coagulation; serine protease 
inhibitor 
51129 ANGPTL4 Angiopoietin-like  N   Angiopoeitin 
2938 GSTA1 Glutathione s-transferase  Y   Detoxification; antioxidant 
2939 GSTA2 Glutathione s-transferase  Y   Detoxification; antioxidant 
2952 GSTT1 Glutathione s-transferase  Y   Detoxification; antioxidant 
221357 GSTA5 Glutathione s-transferase  Y   Detoxification; antioxidant 
5475 PPEF1 Protein phosphatase, EF-hand Ca binding  Y   Regulation of carbohydrate metabolism 
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Table B5.1: Genes Up Regulated by Age - GEO GSE9588 Dataset - Biological Processes [36] 
 

 E
nt
re
z 
 G
en
e 
ID
 
G
en
e 
Sy
m
bo
l 
 G
en
e 
T
yp
e 
D
A
V
ID
 o
r 
PA
N
TH
ER
 
N
ic
ot
in
e 
D
eg
ra
d.
 
E
le
ct
ro
n 
Tr
an
sp
or
t 
Li
pi
d,
 F
at
ty
 a
ci
d,
  
St
er
oi
d 
M
et
ab
ol
. 
St
er
oi
d 
M
et
ab
ol
ism
 S
M
 
St
er
oi
d 
H
or
m
on
e 
M
et
ab
ol
ism
 
Fa
tty
 a
ci
d 
M
et
ab
ol
ism
 
C
ar
bo
hy
dr
at
e 
M
et
ab
ol
ism
 C
M
 
O
th
er
 C
ar
bo
-
hy
dr
at
e 
M
et
ab
ol
. 
D
et
ox
ifi
ca
tio
n 
Parent             
LF
SM
 
SM
 
LF
SM
 
  C
M
 
ID
 
p-value       .0
01
 
E-
08
 
E-
06
 
E-
12
 
E-
04
 
.0
08
 
.0
1 
.0
1 
.0
02
 
Obs 
RefList       
 3 
9 
11 
221 
15 
699 
14 
170 
5 
42 
6 
163 
9 
534 
4 
53 
4
63
124 
125 
126 
ADH1A 
ADH1B 
ADH1C 
Alcohol 
dehydrogenase P             Y Y  
127 ADH4 Alcohol dehydro. P             Y Y  
155 ADRB3 Andrenergic rcpt P                   
635 BHMT Methyltransferase P                   
1543 CYP1A1 Cytochrome p450  DP   Y Y Y   Y       
1548 
1549 
1553 
CYP2A6 
CYP2A7 
CYP2A13 
Cytochrome p450  DP Y Y Y Y   Y       
1555 
1556 
CYP2B6 
CYP2B7 
Cytochrome p450 
CYP pseudogene 
DP 
D  
Y 
-- 
Y 
-- 
Y 
-- 
Y 
--        
1558 CYP2C8 Cytochrome p450  DP   Y Y Y   Y       
1576 
1551 
CYP3A4 
CYP3A7 Cytochrome p450  DP   Y Y Y Y        
1581 
1592 
1595 
CYP7A1 
CYP26A1 
CYP51A1 
Cytochrome p450  DP   Y Y Y           
2938 
2939 
221357 
GSTA1 
GSTA2 
GSTA5 
Glutathione S-
transferase DP                 Y 
2952 GSTT1 "   " DP                 Y 
5105 PCK1 Carboxykinase P             Y     
5475 PPEF1 Phosphatase, Ca P             Y     
6519 SLC3A1 a.a. transporter P             Y     
6716 SRD5A2 Steroid reductase P                   
6718 AKR1D1 Aldoketo reductase P                   
6783 
6822 
SULT1E1 
SULT2A1 Sulfotransferase P     Y Y Y         
6898 TAT T NH3 transferase P                   
7364 UGT2B7 Glucuronosyltransf P     Y Y Y   Y     
8424 BBOX1 Dioxygenase P                   
10891 PPARGC1A Peroxisome recep. P     Y             
134147 CMBL Carboxymethylene-butenolidase hom P             Y     
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Table B5.2: Genes Up Regulated by Age - GEO GSE9588 Dataset - Molecular Function [36] 
 

 E
nt
re
z 
G
en
e 
ID
 
G
en
e 
Sy
m
bo
l 
 G
en
e 
Ty
pe
 
O
xi
do
re
du
ct
as
e 
O
xy
ge
na
se
 
R
ed
uc
ta
se
 
D
eh
yd
ro
ge
na
se
 
T
ra
ns
fe
ra
se
 
O
th
er
 tr
an
sf
er
as
e 
Parent      OR OR OR  T 
p-value     E-11 E-12 .0076 .032 .0027 .0016 
Obs 
Ref List     
19 
550 
12 
94 
6 
157 
6 
205 
12 
799 
6
119
124 
125 
126 
ADH1A 
ADH1B 
ADH1C 
Alcohol 
dehydrogenase Y  Y Y   
127 ADH4 "   " Y  Y Y   
155 ADRB3 Andrenergic rcptr       
635 BHMT Methyltransferase     Y  
1543 CYP1A1 Cytochrome p450  Y Y     
1548 
1549 
1553 
CYP2A6 
CYP2A7 
CYP2A13 
Cytochrome p450  Y Y     
1555 
1556 
CYP2B6 
CYP2B7 Cytochrome p450  
Y 
-- 
Y 
--     
1558 CYP2C8 Cytochrome p450  Y Y     
1576 
1551 
CYP3A4 
CYP3A7 Cytochrome p450  Y Y     
1581 CYP7A1 Cytochrome p450  Y Y     
1592 CYP26A1 Cytochrome P450 Y Y     
1595 CYP51A1 Cytochrome P450 Y Y   Y  
2938 
2939 
221357 
GSTA1 
GSTA2 
GSTA5 
Glutathione S-
transferase     
Y 
Y 
-- 
Y 
Y 
-- 
2952 GSTT1 "   "     Y Y 
5105 PCK1 Carboxykinase       
5475 PPEF1 Phosphatase, Ca       
6519 SLC3A1 a.a. transporter       
6716 SRD5A2 Steroid reductase Y   Y   
6718 AKR1D1 Aldoketo reductase Y  Y    
6783 
6822 
SULT1E1 
SULT2A1 Sulfotransferase     Y Y 
6898 TAT T NH3 transferase     Y  
7364 UGT2B7 Glucuronosyltransf.     Y  
8424 BBOX1 Dioxygenase Y Y     
10891 PPARGC1A Peroxisome recep.       
29947 DNMT3L Methyltransferase     Y  
134147 CMBL Carboxymethylene-butenolidase hom.       
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Table B5.3: Genes Up Regulated by Age - GSE9588 Dataset - Substrates & Functions [35] 

 E
nt
re
z 
G
en
e 
ID
 
Gene 
Symbol  Gene Type 
C
el
lu
la
r 
L
oc
at
io
n 
N
or
m
al
 L
iv
er
 
E
xp
re
ss
io
n?
 
M
ito
ch
on
dr
ia
l?
 
R
ea
ct
iv
e 
O
xi
da
tiv
e 
Sp
ec
ie
s (
R
O
S)
? 
O
be
si
ty
? 
Some substrates 
or Functions 
124 
125 
126 
ADH1A 
ADH1B 
ADH1C 
Alcohol 
dehydrogenase Cyt 
Y 
Hi 
Hi 
   
Alcohol (class I), hydroxysteroids, lipid 
peroxidases 
127 ADH4 "   " Cyt     "   " 
155 ADRB3 Andrenergic recept     Y  
635 BHMT Methyltransferase Cyt     Betainedimethylglycine, homocyst.methionine. 
1543 CYP1A1 Cytochrome p450  ER Y    Induced by PAH (cigarette smoke) 
1548 
1549 
1553 
CYP2A6 
CYP2A7 
CYP2A13 
Cytochrome p450  ER Y    
Nicotine, coumarin, nitrosamines 
Unknown 
Nitrosamine (tobacco). Endo. unknown.
1555 
1556 
CYP2B6 
CYP2B7 Cytochrome p450  ER 
Y 
--    
Some drugs (e.g. anticancer) 
Pseudogene. 
1558 CYP2C8 Cytochrome p450  ER     Drugs (e.g. taxol-cancer) 
1576 
1551 
CYP3A4 
CYP3A7 Cytochrome p450  ER Y    
Half of all drugs. 
Testosterone, estriol formation 
1581 
1592 
1595 
CYP7A1 
CYP26A1 
CYP51A1 
Cytochrome p450  ER 
Y 
Hi 
Hi 
  
Y 
-- 
Y 
Cholesterol degrad. (rate limiting step) 
Retinoic acid - regulation gene express. 
Cholesterol synthesis from lanosterol 
2938 
2939 
221357 
GSTA1 
GSTA2 
GSTA5 
Glutathione S-
transferase Cyt 
Hi 
Hi 
N 
 Y  
Alpha class: Bilirubin, ROS and 
detoxification. 
Expression not detected (other studies). 
2952 GSTT1 Glutathion s-transf. Cyt Low  Y  Theta class: Role in carcinogenesis. 
5105 PCK1 Carboxykinase Cyt  ?  Y Gluconeogen. Insulin reg. Mit isozyme 
5475 PPEF1 Phosphatase, Ca      2+ ER-hand Ca binding at C-term. 
6519 SLC3A1 a.a. transporter  Low    Cysteine, neutral & dibasic a.a. -kidney 
6716 SRD5A2 Steroid reductase      Testosterone, progesterone, corticoster. 
6718 AKR1D1 Aldoketo reductase  Y    Bile acids, steroid hormones. Lohepatic dysfunct. 
6783 
6822 
SULT1E1 
SULT2A1 Sulfotransferase Cyt 
Y 
Hi    
Esterone. Control of estrogen receptors. 
Steroids & bile acids; drugs. 
6898 TAT T NH3 transferase Mit Y Y   L-tyrosine aminotransferase 
7364 UGT2B7 UDP glucuronosyl-transferase 2 ER     
Drugs, estrogens. (Detoxification.) 
8424 BBOX1 Dioxygenase Cyt Mod Y  ? Carnitine biosynthesis  Transport fatty acid mit. 
10891 PPARGC1A Peroxisome recep.  Y Y  Y TF energy metab.; cholest. homeo. 
29947 DNMT3L Methyltransferase Nu     DNA epigenetic transcript. repression. 
134147 CMBL Carboxymethylene-butenolidase hom      
Pseudomodas. 
151531 UPP2 U phosphorylase 2      Pyrimidine metab. Uridine metab. Mostly kidney. 
345275 HSD17B13 Dehydrogenase Sec      
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Table 6:  Genes Down Regulated with Shorter Telomere Length - Ten Sample Set. 
E
nt
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z 
G
en
e 
ID
 
Gene 
Symbol Gene Type 
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C
el
lu
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r 
Lo
ca
tio
n 
Function 
 
TF=transcription factor 
2074 ERCC6 DNA excision repair N Y N Y Nucleus Transcription-coupled. 
4869 NPM1 Nucleolar phospho. N N N Y Nucleolus   
5937 RBMS1 RNA binding motif N Y N Y Nucleus DNA repl?  Binds ssDNA upstream of c-myc 
6165 RPL35A Ribosomal protein N Y N N Cytoplasm Part of rib. 60S subunit 
7182 NR2C2 Nuclear receptor; N Y N Y   TF. Devel. orphan recept. 
8359 
8366 
8364 
8360 
8367 
8361 
8365 
8294 
8363 
8362 
8368 
8370 
554313 
121504 
HIST1H4A 
HIST1H4B  
HIST1H4C 
HIST1H4D 
HIST1H4E 
HIST1H4F 
HIST1H4H 
HIST1H4I 
HIST1H4J 
HIST1H4K 
HIST1H4L 
HIST2H4A 
HIST2H4B 
HIST4H4 
Histone H4 Y Y Y Y Nucleus 
14 variants of Histone H4 
One of four core proteins 
making up the 
nucleosome, the core unit 
of DNA. 
 
8666 EIF3S4 Eukaryotic trans-lation initiation factor N Y N N   
Promotes binding of 
mRNA and tRNA 
9678 PHF14 PHD finger protein N Y N Y     
9705 ST18 Myelin transcription factor 1 N N N Y   
Represses basal transcript 
act. from target promoters. 
9991 ROD1 Regulator of Differentiation N Y N Y   
Suppresses onset of differ-
entiation. Nrd1 homolog. 
10629 TAF6L TAF6-like RNA polymerase II N N Y Y Nucleus 
Part of PCAF complex; 
acetylates histones. 
10919 EHMT2 Methyltransferase N Y Y Y Nucleus Methylates histone H3, H1
11317 RBPSUHL Recombining binding protein  N Y N Y   
Transcr. factor w/EBNA2? 
Suppressor of hairless. 
23521 RPL13A Ribosomal protein N Y N N Cyt Part of 60S subunit. 
29396 unassigned Transformer-2 alpha N Y N Y   Myelin transcription factor
54993 ZSCAN2 Zinc finger and SCAN domain N Y N Y Nucleus 
Transcript regulation post-
meiotic spermatogenesis? 
55198 unassigned DIP13 Beta N Y N N Mem, nuc Regulation of cell prolif. 
56907 SPIRE1 Spire homolog N N N Y   Actin organization. 
64843 ISL2 ISL2 transcript factor N Y N Y Nucleus TF; subclass of moto-neurons of spinal cord. 
80345 ZNF435 Zinc finger protein N Y N Y   Transcription regulation? 
126820 WDR63 Testis develop. prot. N N N Y     
171017 ZNF384 Zinc finger protein N Y N Y Nucl. TF. MMP. Discontinued? 
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Appendix C  Excel Codes 
 
 
Sample Set A - Ten Liver Sample Dataset 
 
Preprocessing:  Adjustments, modifications and averaging of data, and ANCOVA macro. 
(Note: no similar processing was needed for Sample Set B - GEO GSE9588.) 
 
Data Processing Overview: 
1. Correct Gene ID codes. 
2. Remove data points which fail the quality control. 
3. Raise all intensities to the minimum, the Negative TrimMean Control. 
4. Transform data to log 2, and then average. If a data point is missing, use the other value. If both 
are missing, mark "Missing."  If the replicas differ by more than 8 fold, remove the average data 
point. 
5. Determine the number of data points not omitted. (If more than one missing, omit gene.) 
6. Determine the skew of the data for a single gene. Remove that gene if the absolute value of the 
skewness is greater than two times the Standard Error of Skewness (SES=√6/n) 
7. Determine the kurtosis of the data for a single gene. Remove that gene if the absolute value of the 
kurtosis is greater than two times the Standard Error of Kurtosis (SEK = √24/n). 
8. Copy data to a new sheet. 
9. Check data. 
10. Run ANCOVA macro for each gene using XL-STAT. (www.xlstat.com) 
11. Check that probe IDs match. 
12. Search DAVID for equivalent reference sequence gene identification numbers. 
13. Find ANCOVA genes in a specific list of inflammation and ROS genes, for closer analysis. 
14. Extract the slope of the ANCOVA line, to determine the direction of expression. 
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1. Remove .1 suffix from the ACCN#, for recognition by DAVID, etc. 
=LEFT(B2,LEN(B2)-2) 
 
2. Mark microarray values with quality control "C", "M" or "I" as "Missing" 
 
3. Raise numbers to the Negative TrimMean Control for that specific sample. 
=IF('LGSMI All'!H2="Missing","Missing",IF('LGSMI 
All'!H2<0.679853734,0.679853734,'LGSMI All'!H2)) 
 
4. Take the log base 2 of the numbers, and then average them. 
If both values are missing, mark "Missing" 
If one of the values is missing, the "average" is log2 of the other value. 
If the variance between the two values is greater than 8 fold, mark "Variance". 
For all others, take the log base 2, and then average the two numbers after. 
Result:  7,257 had a variance greater than 8x 
Result:  2,200 had both data points missing. 
 
=IF(AND('To TrimMean'!F2="Missing",'To TrimMean'!G2="Missing"),"Missing", IF('To 
TrimMean'!F2="Missing",LOG('To TrimMean'!G2,2), IF('To TrimMean'!G2="Missing",LOG('To 
TrimMean'!F2,2),IF(ABS(LOG('To TrimMean'!F2,2)-LOG('To 
TrimMean'!G2,2))>3,"Variance",AVERAGE(LOG('To TrimMean'!F2,2),LOG('To 
TrimMean'!G2,2)))))) 
 
5. Determine the number of data points not omitted. 
= Count(F2:O2) 
 
6. Determine the skewness of the distribution. Mark as 99 if the number of valid data points is less 
than 4. 
=IF(P3<4,99,SKEW(F3:O3)) 
 
7. Determine the kurtosis of the distribution. Mark as 99 if the number of valid data points is less 
than 5. 
=IF(P2<5,99,KURT(F2:O2)) 
 
8. Copy the values and paste into a new sheet. Convert the "Missing" and "Variance" to "NA" for the 
ANCOVA analysis using the Replace tool, which is what XL-STAT requires for missing data 
points. 
Paste special  values 
 
9. Check the data that all values are within -2 and 10 (which is the log2 of 0.25 and 1064) or are 
marked NA (no value - "Missing" or "Variance"). 
=OR(AND('Y Variable'!G2<10,'Y Variable'!G2>-2),'Y Variable'!G2="NA") 
Results:  One value was 10.005. All others confirmed. Confirmation data omitted. 
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10. XL-STAT Macro for ANCOVA (Age-Disease and Telomere-Disease) 
Adjusted slightly for each run. i = 1 to 49584.  Run in sets of 3,000 to prevent RAM-related 
computer crashes. 
 
Sub ANCOVADisease() 
    Dim i As Long 
     
    For i = 49001 To 49584 
         
        Call LoadRunANCO(Sheets("Y Variable").Range("F" & 1 + i & ":O" & 1 + i), _ 
                         Sheets("X Variable").Range("F2:O2"), _ 
                         Sheets("X Variable").Range("F3:O3"), _ 
                         NoScreenUpdating:=True) 
 
        DoEvents 
        With Sheets("Results").[E1] 
            .Offset(i) = ActiveSheet.Range("C37") 
            .Offset(i, 1) = ActiveSheet.Range("C39") 
            .Offset(i, 2) = ActiveSheet.Range("C40") 
            .Offset(i, 3) = ActiveSheet.Range("C41") 
            .Offset(i, 4) = ActiveSheet.Range("C42") 
            .Offset(i, 5) = ActiveSheet.Range("C43") 
            .Offset(i, 6) = ActiveSheet.Range("C44") 
            .Offset(i, 7) = ActiveSheet.Range("E55") 
            .Offset(i, 8) = ActiveSheet.Range("E56") 
            .Offset(i, 9) = ActiveSheet.Range("F55") 
            .Offset(i, 10) = ActiveSheet.Range("G55") 
            .Offset(i, 12) = ActiveSheet.Range("F64") 
            .Offset(i, 13) = ActiveSheet.Range("G64") 
            .Offset(i, 14) = ActiveSheet.Range("F65") 
            .Offset(i, 15) = ActiveSheet.Range("G65") 
            .Offset(i, 16) = ActiveSheet.Range("F66") 
            .Offset(i, 17) = ActiveSheet.Range("G66") 
            .Offset(i, 19) = ActiveSheet.Range("F72") 
            .Offset(i, 20) = ActiveSheet.Range("G72") 
            .Offset(i, 21) = ActiveSheet.Range("F73") 
            .Offset(i, 22) = ActiveSheet.Range("G73") 
            .Offset(i, 23) = ActiveSheet.Range("F74") 
            .Offset(i, 24) = ActiveSheet.Range("G74") 
            .Offset(i, 25) = ActiveSheet.Range("B92") 
             
            Application.DisplayAlerts = False 
            ActiveSheet.Delete 
             
        End With 
 
    Next i 
 
    Application.DisplayAlerts = True 
 
End Sub 
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11. Check that the probe analyzed in the results (given in the equation of the model) matches the 
probe and description listed, and matches the same probe on the line in the y variable. The probe 
names all start with GE and have at least 7 characters. Filter to examine any that are marked 
"False."  Result: only those not analyzed (i.e. n<8) came up "False." 
=LEFT(AD2,7)=LEFT(D2,7) 
=LEFT(AD2,7)=LEFT('Y Variable'!F2,7) 
 
12. Search DAVID for equivalent mRNA reference sequences in non NM_ gene ascension numbers. 
Get the NM_ number and the gene description. Mark those descriptions which are unusable:  ORF, 
Hypothetical proteins, Hypothetical genes, KIAA, Incyte unique probes and LOC. Copy and paste 
these into the ACCN# column, and sort by this column. Then use the following code to copy and 
paste the new ID and description into that column. 
=IF(AND(B2=B4,NOT(B4="")),E4,IF(B2=B3,E3,"")) 
 
13. Find the ANCOVA results from a list specific genes related to inflammation and reactive 
oxidative species (ROS). 
a. Copy and paste the ANCOVA results into a new file, to avoid inadvertent contamination 
of the results. 
b. Insert columns for the acronym and group number. 
c. Set up the blank cells to copy the line below it if the genes are the same. 
=IF(I2=I3,E3,"") 
d. Cut and paste the list of genes of interest, so that the GE… ID numbers are in the same 
column. 
e. Sort the data by gene (GE…) 
f. Set up a column to identify if the genes are the same. 
=I2=I3 
g. Auto filter by that column, those marked "True". Copy and paste those genes into a new 
worksheet. State which ANCOVA analysis they come from (Age-Tel, Age-Dis or Tel-
Dis). 
 
14. Extract the slopes from the overall equation of the model in the Age-Tel group. (There are no 
spaces in the original equation. They were added here for readability. LEN (length) = # of 
characters in a cell. LEFT & RIGHT = Take the first x number of characters starting from the left 
or right side, respectively. MID = Take the middle characters. FIND = Find the first character (or 
word); returns the number of characters. 
a. AD2-Start:  GE545180 = -12.0993263871198 + 0.302036367147246*Age + 
1.40056410472251*Telomere Length - 0.034985998351747*Age*Telomere Length 
b. AJ2-Right side:  =RIGHT(AD2,LEN(AD2)-FIND("=",AD2,3)) 
c. AK2-Left 2 terms:  =LEFT(AJ2,FIND("*",AJ2,1)-1) 
d. AL2-Left term:  =LEFT(AK2,FIND(".",AK2,6)-3) 
e. AM2-Account for single vs. double digit 2nd term (10.00 vs. 9.00): =RIGHT(AL2,1) 
f. AO2-Intercept slope:  =IF(OR(AM2="+",AM2="-"),LEFT(AL2,LEN(AL2)-1), AL2) 
g. AP2-2nd term:  =RIGHT(AK2,LEN(AK2)-LEN(AO2)) 
h. AQ2-Check sign of the term, to remove the '+'. 
i. AS2-Age slope:  =IF(AQ2="-",AP2,RIGHT(AP2,LEN(AP2)-1)) 
j. AT2-Last two terms:  =RIGHT(AJ2,LEN(AJ2)-LEN(AK2)-4) 
k. AU2-Sign of third term, to remove the '+':  =LEFT(AT2,1) 
l. AW2-Telomere Length:  =IF(AU2="-", LEFT(AT2,FIND("*",AT2,2)-1), 
MID(AT2,2,FIND("*",AT2,2)-2)) 
m. AX2-Last term:  =RIGHT(AT2,LEN(AT2)-LEN(AW2)-17) 
n. AY2-Sign of last term, to remove the '+':  =LEFT(AX2,1) 
o. BA-Age-Telomere:  =IF(AY2="-", LEFT(AX2,FIND("*",AX2,2)-1), 
MID(AX2,2,FIND("*",AX2,2)-1)) 
p. Convert from formulae to numbers, to stabilize: 
i. Copy  Edit  Paste Special  Value 
ii. Convert from text to a number value  ('!' icon next to cell) 
